42.88

4.25% 1.75

After Hours: 42.88

Sionna Therapeutics Inc (SION)

Overview News Price History Discussions Forecast

Sionna Therapeutics Inc stock is traded at $42.88, with a volume of 188.79K. It is up +4.25% in the last 24 hours and up +12.52% over the past month. Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.

Previous Close:

$41.13

Open:

$41.68

24h Volume:

188.79K

Relative Volume:

0.52

Market Cap:

$1.94B

Revenue:

Net Income/Loss:

$-75.27M

P/E Ratio:

-25.28

EPS:

-1.6963

Net Cash Flow:

$-66.67M

1W Performance:

+13.80%

1M Performance:

+12.52%

6M Performance:

-2.08%

1Y Performance:

+237.11%

1-Day Range:

$40.53

$43.16

1-Week Range:

$36.90

$43.41

52-Week Range:

$12.53

$48.45

Sionna Therapeutics Inc Stock (SION) Company Profile

Name

Sionna Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

617-819-2020

Address

21 HICKORY DRIVE, SUITE 500, WALTHAM

Employee

Twitter

Next Earnings Date

2026-05-11

Latest SEC Filings

SION's Discussions on Twitter

Compare SION vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SION Sionna Therapeutics Inc	42.88	1.86B	0	-75.27M	-66.67M	-1.6963
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-26	Initiated	Citizens	Mkt Outperform
Dec-01-25	Downgrade	RBC Capital Mkts	Sector Perform → Underperform
Nov-19-25	Initiated	BTIG Research	Buy
Sep-03-25	Initiated	RBC Capital Mkts	Sector Perform
Sep-03-25	Initiated	Raymond James	Strong Buy
Mar-04-25	Initiated	Guggenheim	Buy
Mar-04-25	Initiated	Stifel	Buy
Mar-04-25	Initiated	TD Cowen	Buy

View All

Sionna Therapeutics Inc Stock (SION) Latest News

08:41 AM

Stifel reiterates Buy on Sionna Therapeutics stock ahead of data By Investing.com - Investing.com Canada

08:41 AM

05:33 AM

Citizens reiterates Sionna Therapeutics stock rating on CF treatment potential By Investing.com - Investing.com Canada

05:33 AM

May 24, 2026

Number of shareholders of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView

May 24, 2026

A Quick Look at Today's Ratings for Sionna Therapeutics(SION.US), With a Forecast Between $50 to $63 - Moomoo

May 24, 2026

May 21, 2026

Freedom Broker downgrades Sionna Therapeutics (SION) - MSN

May 21, 2026

May 20, 2026

SION: Phase II data for two NBD1 stabilizers in CF expected this summer, aiming for superior efficacy - TradingView

May 20, 2026

Sionna Therapeutics Cut to Hold From Buy by Freedom Broker - Moomoo

May 20, 2026

Sionna Therapeutics Price Target Maintained With a $38.00/Share by Freedom Broker - Moomoo

May 20, 2026

Sionna Therapeutics stock rating cut to Hold at Freedom Broker By Investing.com - Investing.com Canada

May 20, 2026

May 19, 2026

SION Maintained by Stifel -- Price Target Raised to $55 - GuruFocus

May 19, 2026

May 18, 2026

Sionna Therapeutics Price Target Raised to $55.00/Share From $44.00 by Stifel - Moomoo

May 18, 2026

Wedbush Maintains Sionna Therapeutics(SION.US) With Buy Rating, Maintains Target Price $53 - Moomoo

May 18, 2026

Stifel raises Sionna Therapeutics price target on NBD1 data confidence By Investing.com - Investing.com Canada

May 18, 2026

May 17, 2026

User - FinancialContent

May 17, 2026

May 16, 2026

Wedbush initiates coverage of Sionna Therapeutics (SION) with outperform recommendation - MSN

May 16, 2026